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PURPOSE
  Stress urinary incontinence (SUI) is the complaint of invol-
untary leakage of urine on effort or exertion, or on sneezing 
or coughing in women.1 Approximately three quarters of women 
with incontinence present with the symptom of SUI in either 
pure or mixed forms.1 SUI prevalence rates may be different 
between ethnic groups.1,2 There are a limited number of epi-
demiologic studies evaluating urinary incontinence in Asian 
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Purpose: To compare duloxetine with placebo for the treatment of Korean 
women with stress urinary incontinence (SUI).
Materials and Methods: This was a phase 3, double-blind, stratified, 
randomized, parallel, placebo-controlled, multi-center study investigating 
efficacy and safety of a of duloxetine compared with placebo in the 
treatment of SUI. After a 2-week no-drug screening period, women ages 
29-69 were randomly assigned to placebo (n=60) or duloxetine (n=61) as 
40mg twice daily for 8 weeks followed by a 2 week no-drug period. 
Women were seen at 4-week intervals. The primary efficacy variable was 
percent change in incontinence episodes frequency (IEF)/week. Secondary 
variables included percent change in, changes in Incontinence Quality of 
Life (I-QoL) total and 3 sub-scale scores, and Patient Global Impression 
of Improvement (PGI-I) ratings. Safety was evaluated by treatment emer-
gent adverse events (TEAE), discontinuations due to adverse events, vital 
signs measurements, and clinical laboratory tests.
Results: There were statistically significant improvements with duloxetine 
compared with placebo in IEF (duloxetine baseline 16.4IEF/wk, endpoint 
7.7IEF/wk, median percent reduction=50.0% vs placebo baseline 13.3IEF/ 
wk, endpoint 8.8IEF/wk, median percent reduction=37.1%, p=0.033), and 
avoidance and limiting behavior subscale (p=0.006) in I-QoL. TEAEs were 
reported significantly more often in the duloxetine group compared with 
the placebo group (82.0% vs 31.7%; p＜0.001); common AEs (≥5% in 
duloxetine-treated subjects and p＜0.05) were nausea, dizziness, anorexia, 
fatigue, lethargy, abdominal discomfort, and constipation. Discontinua-
tion rates because of AEs were 34.4% for duloxetine and 8.3% for placebo.
Conclusions: These data provide evidence for the safety and efficacy of 
duloxetine for the treatment for Korean women with SUI. (Korean J Urol 
2006;47:527-535)
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women. Available studies list prevalence rates for urinary 
incontinence in Asian women ranging from 4.8-53.7%.3-6 In a 
study of 1,303 Korean women, 41.2% reported urinary incon-
tinence, comprising 37.8% with SUI, 18.0% with urge urinary 
incontinence, 14.9% with mixed urinary incontinence and .4% 
with an unclassified form.2 Differences in urinary incontinence 
definitions, types or severity of urinary incontinence, studied 
populations, as well as study design, and means of data as-
sessment and collection are responsible for the wide prevalence 
estimates. 
  SUI results when the urethra is unable to maintain a positive 
closure gradient compared with the bladder when physical 
activities cause an increase in abdominal pressure. Factors 
associated with the inability to maintain urethral closure include: 
(1) an anatomic failure to maintain support of the proximal 
urethra and bladder neck, (2) neuromuscular damage to the 
pelvic floor and urethra, and (3) weakness of the intrinsic 
urethral closure mechanism.1 Traditional SUI treatments have 
been directed at correcting or compensating what was considered 
mainly an anatomical defect with behavioral interventions, 
pelvic floor muscle training (PFMT), or surgery rather than 
pharmacological intervention.1
  Despite the high degree of bother associated with SUI and 
concomitant impact on quality of life, only approximately 25- 
33% of American and European women with UI seek help.7-10 
The number of treatment seekers in North America increases 
with severity of SUI (54% in women with severe UI),10 but 
behavioral interventions are seen as coping mechanisms rather 
than as treatments, compliance with PFMT programs is low, 
and limited availability of surgery and associated surgical 
complications decrease the viability of surgery as an option. 
Different pharmacological agents have previously been used 
off-label, but an evidence-based pharmacological treatment has 
not been available until recently.1 
  Numerous animal studies have implicated serotonin (5-HT) 
and norepinephrine (NE) in the central control of lower urinary 
tract function. In non-rodent species, serotonergic agonists 
suppress parasympathetic activity and enhance sympathetic and 
somatic activity in the lower urinary tract11 promoting urine 
storage by relaxing the bladder and increasing outlet resistance. 
Noradrenergic agonists and antagonists variably affect sympa-
thetic and somatic activity in the lower urinary tract, depending 
on the adrenergic receptor subtype.11 Duloxetine hydrochloride, 
a dual serotonin and norepinephrine reuptake inhibitor (SNRI) 
with little or no affinity for cholinergic receptors has demon-
strated to increase bladder capacity and striated urethral sphin-
cter activity presumably through central actions in the spinal 
cord in cats.11 The ability of duloxetine to centrally stimulate 
pudendal motor neurons and increase striated urethral sphincter 
tone and contractility is thought to be the basis for its efficacy 
in women with SUI.
  In August 2004, duloxetine became the first medication 
approved for the treatment of women with moderate to severe 
SUI throughout the European Union, a number of countries in 
North and South America, and Israel. Regulatory approval was 
primarily based on the demonstration of the safety and efficacy 
of duloxetine in 4 randomized placebo-controlled core registra-
tion trials enrolling 1,913 women from Africa, Australia, Eu-
rope, and North and South America.12-15 This study was 
conducted to comply with local Korean regulatory requirements 
as a supplement to these existing core trials. The primary 
objective was to compare the efficacy and safety of duloxetine 
80mg/day (administered as 40mg twice daily) with that of 
placebo in the treatment of Korean women with a predominant 
symptoms of SUI.
MATERIALS AND METHODS
  Non-pregnant women 20 years of age and older with predo-
minant symptoms of SUI at least 3 months in duration were 
enrolled in this double-blind, placebo-controlled, randomized, 
parallel, clinical trial conducted at 7 study centers in Korea. The 
study design was reviewed by a local ethics committee and 
written informed consent was obtained from all participants. 
Concomitant medications including urinary continence promo-
ting drugs, antidepressants, drugs for obesity (including over- 
the-counter appetite suppressants and diet pills), and illicit drugs 
were not allowed in the study. Enrolled women reported the 
predominant symptoms of SUI during the last 3 months with 
at least ≥1 incontinent episode/day. Additional history require-
ments included daytime voiding frequency ≤8 voids daily, 
nocturnal frequency ≤2 voids daily and no predominant urge 
incontinence symptoms. All women had a retrograde bladder 
filling performed. With the patient supine the bladder was filled 
with saline at 100ml/min via a catheter with no pressure mea-
surements. Patients who were unable to tolerate this simple 
filling cystometry procedure to 400ml were excluded, as were 
those who experienced a first sensation of bladder filling at ＜100 
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ml, or who had no sensation at any time during the filling. A 
positive cough stress test with visualization of urine leakage 
concurrent with a cough was required after filling the blad-
der.12-15
  Fig. 1 provides an overview of the study design and timing 
of acquisition of diaries and other variables. After a 2-week, 
no drug, lead-in period, women were randomly assigned under 
double-blind conditions to 8 weeks of 80mg/day (40mg twice 
daily) of duloxetine or placebo administered as 2 identical
(20mg) capsules twice daily. Women were evaluated at 4-week 
intervals. The treatment phase of the core registration trials was 
12-weeks; however, the majority of the these adverse events 
emerged within the first 4 weeks and the number of duloxetine 
responders (≥50% reduction in median percent incontinence 
episode frequency [IEF]) did not change significantly after 4 
weeks post-randomization. Randomization was controlled by a 
computerized interactive voice response system at a central 
location for all study sites. Stratified randomization using 
baseline IEF of ＜14 or ≥14 episodes/week obtained from 
patient diaries was used to prevent potential imbalance in 
incontinence severity.
  Weekly paper diaries were also used to collect the number 
of voids, the time of voids, the time study medication was taken, 
and the number of continence pads used. Diaries were collected 
to determine baseline incontinence severity the last week before 
visit 2 during the no drug lead-in period (Fig. 1).
  The primary efficacy variable in this study was percent chae 
in IEF/week from baseline to endpoint, which was calculated 
from subject completed, real-time, paper diaries. Approximately 
50% reduction in IEF has been generally accepted as a clinically 
relevant threshold for response in SUI outcomes research for 
interventions such as bladder training and PFMT,16 devices,17 
surgery,18,19 and a pharmacological agent.12-15 That convention 
was followed in this paper and an IEF responder was defined 
as a woman who had at least a 50% decrease in IEF with 
treatment.
Secondary efficacy variables included: 1) Incontinence 
Quality of Life (I-QoL) questionnaire total and subscale scores,20 
2) Patient Global Impression of Improvement (PGI-I) rating,21 
3) time between voids/day, and 4) continence pad use/week.
  The I-QoL questionnaire is a globally-validated, disease- 
specific instrument endorsed by the International Consultation 
on Incontinence, which was administered at each visit and 
evaluates the effects of urinary incontinence in 3 domains: 
avoidance and limiting behavior, social embarrassment, and 
psychosocial impact. An I-QoL score of 100 represents the best 
possible quality of life and 0 represents the worst possible 
quality of life. To ensure appropriate translation the question-
naire was linguistically validated.22
  The PGI-I rating is a globally-validated 1-question question-
naire and was obtained at each post-randomization visit. The 
PGI-I measures subject self-perceived improvement in the 
condition since starting treatment with a single question.21 To 
ensure appropriate translation the questionnaire was translated 
from English to Korean and than back to English.
  Compliance with the required study drug regiment was 
examined at each visit following initiation of treatment. Unused 
study drug was returned to Eli Lilly and Company, and 
compliance was assessed by counting returned study drug. 
Investigators encouraged compliance with study medication but 
subjects were not discontinued from the study for poor com-
pliance only.
  Safety was assessed by evaluation of treatment-emergent 
adverse events (TEAEs), discontinuations due to adverse events, 
serious adverse events, discontinuation emergent adverse events, 
vital signs measurements, and clinical laboratory tests. Adverse 
events were elicited by nonprobing inquiry at each visit and 
Fig. 1. Study design and the timing of acquiring the urinary diaries 
and reports on the quality of life measurements. I-QoL: Incontinence 
Quality of Life questionnaire, PGI-I: Patient Global Inpression of 
Improvement.
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were recorded regardless of perceived causality. An event was 
considered treatment emergent if it occurred for the first time 
or worsened during the double-blind treatment period.
  A serious adverse event was defined according to the 
International Consultation on Harmonization guidelines and 
included any adverse events associated with death, initial or 
prolonged inpatient hospitalization, a life-threatening experience
(ie, immediate risk of dying), persistent or significant disa-
bility/incapacity, congenital anomaly/birth defect, or is signi-
ficant for any other reason.
  The statistical analysis plan was specified a priori and was 
performed in accordance with intent-to-treat (ITT) principles. 
Subjects with baseline and at least 1 post-baseline measurement 
were included in the analysis. The percent change in IEF was 
compared between treatment groups using the van Elteren's test, 
a type of stratified Wilcoxon test, with baseline incontinence 
severity as the stratification variable. This primary analysis 
compared IEF before and after randomization, pooling all diaries 
between visits 1 and 2 for the baseline and all diaries between 
visits 2 and 4 for the end point. The changes in I-QoL scores 
were analyzed using an ANCOVA model that included terms 
for baseline scores, treatment, site, and baseline incontinence 
severity. The endpoint PGI-I was analyzed using the Cochran- 
Mantel-Haenszel test with the baseline incontinence severity as 
the strata. The missing values in the above analyses were 
imputed via LOCF.
  Enrollment in the study was set to end when approximately 
120 women (60 per treatment group) had been assigned to a 
treatment group. The sample size was determined to provide 
97.3% power for detecting a treatment difference of 23% in the 
median percent change in IEF from baseline to endpoint.
  Analyses were performed using SAS 8.1 (SAS Institute, Cary, 
USA). A two-sided alpha level of 0.05 was considered statis-
tically significant for treatment effects.
RESULTS
  A total of 121 women 29-69 years of age were randomly 
assigned to receive duloxetine 80mg/day (n=61) or placebo
(n=60) between December 2003 and October 2004. Approxi-
mately 81% of women completed at least 1 post-randomization 
diary (73.8% duloxetine, 88.3% placebo), while 93.3% com-
pleted at least 1 I-QoL questionnaire (91.8% duloxetine, 95% 
placebo). In total, 68.6% of women completed the 8-week study
(60.7% duloxetine, 76.7% placebo).
  Table 1 shows the baseline clinical characteristics of the 
women randomized to each treatment group. The only stati-
stically significant baseline difference between treatment groups 
was for time between voids, with the duloxetine treatment group 
having less time between voids than the placebo treatment 
group.
  On average, patients in the placebo group took 74% of their 
treatment doses compared with 60% of doses in the duloxetine 
group (p=0.016). This difference in compliance was due to 
limited duloxetine consumption by subjects who discontinued 
from the trial early and was not significant after the first post- 
randomization visit.
  The decrease in IEF, as demonstrated by median percent 
change, was significantly greater in the duloxetine group than 
in the placebo group (Table 2). The improvements with duloxe-
tine were observed at the first post-randomization visit (4 weeks) 
and were maintained throughout the study. Overall, 51% of 
duloxetine-treated subjects and 35.8% of placebo-treated sub-
jects were IEF responders (p=0.128).
  The duloxetine treatment group demonstrated numerically, 
although not statistically significant, improvement in the I-QoL 
total score and in 2 of the 3 I-QoL subscale scores when 
compared with the placebo treatment group (Table 3A, 3B). The 
Table 1. Baseline* clinical characteristics for all the randomized 
women
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  Duloxetine    Placebo
ꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏ
Randomized N†  61  60
Age, years  50.67 (±9.01)  48.52 (±8.05)
BMI, kg/m2‡  23.77 (±2.46)  23.42 (±3.17)
IEF/week (SD)  15.74 (±11.35)  13.27 (±7.04)
[range]    [3.0-59.0]   [6.42-41.42]
Mean time between
 215.86 (±60.72) 241.90 (±56.40)
  voids, min
Total I-QoL score  49.37 (±21.57)  51.38 (±20.66)
Previou scontinence
        3        2
 surgery
ꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏ
*: Baseline is the last visit score on or prior to randomization, †: 
Every randomized subject did not provide information for each 
variable; percentages are calculated using the number of responding 
women as the denominator, ‡: 0.01. Data are means (SD) unless 
otherwise indicated, BMI: body mass index, PFMT: pelvic floor 
muscle training, IEF: incontinence episode frequency, I-QoL: 
Incontinence Quality of Life questionnaire.
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mean change in the I-QoL subscale “Avoidance and Limiting 
Behavior” score showed a statistically significant difference in 
favor of duloxetine when compared to placebo (15.57 vs 6.25; 
p=0.006).
  The analysis of the PGI-I data revealed results similar to those 
observed with the I-QoL analysis. Only a few more women in 
the duloxetine group than in the placebo group considered their 
urinary tract condition to be ‘very much better, much better, 
or a little better' (35 vs 33, respectively).
  The change in mean time between voids/day was significantly 
greater for duloxetine-treated women when compared with 
change in placebo-treated women (34.33 vs －3.61 minutes, res-
pectively; p＜0.001). Women in the duloxetine group used 
significantly less continence pads compared with those in the
placebo group (－3.82 vs －1.65, respectively; p=0.040).
  TEAEs were experienced by significantly more women in the 
duloxetine group compared with the placebo group (82.0% vs 
31.7%; p＜0.001). Table 4 lists all of the adverse events that 
occurred in at least 5% of women on duloxetine, or that were 
statistically significantly more common with duloxetine. Nausea 
was the most common adverse event in the study. Most nausea 
was reported early in the study, 65% was mild to moderate in 
severity at onset, and in no instance did it increase in severity. 
The majority (18 of 23; 78.3%) of women that developed nausea 
remained on the study. Of these, 11.1% reported resolution of 
nausea within 1-3 days, 38.9% within 1 week, 66.7% within 
2 weeks and 88.9% within 1 month.
  For women who remained in the study despite experiencing 
these TEAEs, the majority had resolution of the event within 
30 days (abdominal discomfort 4 of 6, 67%; anorexia 16 of 17, 
94%; constipation 3 of 6, 50%; dizziness 18 of 19, 95%; fatigue 
7 of 9, 78%; lethargy 4 of 4, 100%; nausea 16 of 18, 89%).
  The discontinuation rate due to adverse events was signifi-
cantly greater for the duloxetine group compared with the 
placebo group (34.4% vs 8.3%; p＜0.001). The most common 
adverse events leading to discontinuation (≥5% in the duloxe-
Table 2. Frequency of incontinence episodes
ꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚ
Treatment Absolute mean Median percent 95% CI for medianTime point n†  pgroup (N)* IEF/week change from baseline percent change in IEF
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Placebo (60) Baseline 53   11.00
Endpoint    6.72
Change  －3.83 －37.14 －45.45, －27.27
Duloxetine (61) Baseline 45   12.92
Endpoint    6.13
Change  －6.54 －50.00 －60.20, －40.91 0.033
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*N: number randomized, †n: number with diary data available for specified analysis, CI: confidence interval, IEF: incontinence episode 
frequency
Table 3A. Incontinence Quality of Life questionnaire: subscale scores
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I-QoL total scoreTreatment Time point n† ꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏgroup (N)*  Mean change in I-QoL 95% CI for treatmentMean I-QoL pfrom baseline‡ difference in I-QoL§
ꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏ
Placebo (60) Baseline 57 51.52
Endpoint 60.23  8.71
 Duloxetine (61) Baseline 56 48.64
Endpoint 63.41 14.77 －0.37,11.16 0.066
ꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏ
*N: number randomized, †n: number with diary data available for specified analysis, ‡: Baseline is the last nonmissing visit score on 
or before randomization, §: 95% CI for treatment difference. CI: confidence interval, I-QoL: Incontinence Quality of Life questionnaire
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tine treatment group) were fatigue, lethargy, and nausea. Table 
5 lists all adverse events that resulted in a 1% or higher 
discontinuation rate for duloxetine.
  There was a statistically significant increase in mean heart 
rate during treatment with duloxetine compared with placebo; 
however, the ＞3 beats per minute increase with duloxetine was 
within the normal range. There were no statistically significant 
differences in the mean change for systolic or diastolic blood 
pressure between duloxetine and placebo groups. Clinical labo-
ratory assessments, vital signs, and physical findings were stable 
relative to baseline and no clinically relevant differences were 
Table 4. Treatment-emergency adverse events occurred in ≥5% 
of the women randomized to the duloxetine group or they occurred 
significantly more often with duloxetine than with placebo
ꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚ
Duloxetine Placebo    p (n=61) (n=60)
ꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏ
Total number of women
 50 (82) 19 (31.7) ＜0.001
  with ≥1 TEAE
ꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏ
Nausea  23 (37.7)  4 (6.7) ＜0.001
Dizziness  20 (32.8)  2 (3.3) ＜0.001
Anorexia  17 (27.9)  2 (3.3) ＜0.001
Fatigue  14 (23.0)  1 (1.7) ＜0.001
Lethargy   9 (14.8)  0 (0.0)   0.003
Abdominal discomfort   8 (13.1)  1 (1.7)   0.032
Somnolence   7 (11.5)  1 (1.7)   0.061
Constipation   6 (9.8)  0 (0.0)   0.027
Headache   6 (9.8)  5 (8.3)   0.999
Dry mouth   5 (8.2)  2 (3.3)   0.439
ꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏ
Values are expressed as n (%).
Table 5. Discontinuations due to adverse events occurred in ≥1% 
of women randomized to the duloxetine group
ꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚ
Duloxetine Placebo     p (n=61)  (n=60)
ꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏ
For any adverse event  21 (34.4)   5 (8.3)   0.001
Fatigue   5 (8.2)   0 (0.0)   0.057
Lethargy   5 (8.2)   0 (0.0)   0.057
Nausea   5 (8.2)   1 (1.7)   0.207
Abdominal discomfort   2 (3.3)   0 (0.0)   0.496
Disturbance in attention   1 (1.6)   0 (0.0) ＞0.999
Dizziness   1 (1.6)   1 (1.6) ＞0.999
Dyspepsia   1 (1.6)   0 (1.6) ＞0.999
ꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏ
Values are expressed as n (%).
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detected between treatment groups. There were 3 discontinuation 
emergent adverse events reported during the last 2-week no-drug 
observation period, 2 associated with placebo treatment (1 
woman had abdominal pain and 1 woman needed surgery) and 
1 with duloxetine treatment (woman experienced dizziness, 
headache and nausea). There were no serious adverse events 
including deaths in this study.
DISCUSSION
  In this study of Korean women with predominant SUI, 
duloxetine 80mg/day (40mg twice daily) as measured by the 
primary efficacy analysis (median percent change in IEF/week) 
and several of the secondary analyses (I-QoL “Avoidance and 
Limiting Behavior” subscale, mean time between voids/day, and 
percent change in continence pad use/week) was noted to be 
significantly more effective than placebo. The significant reduc-
tions in SUI episodes and numerical improvements in I-QoL 
and PGI-I scores with duloxetine compared with placebo in this 
non-core registration trial are consistent with responses in core 
registration trials conducted in Europe, North America, South 
America, Australia and Africa.12-15
  Most Korean women treated with duloxetine did not eliminate 
their SUI; however, duloxetine-associated treatment effect was 
apparent within the first 4 weeks of treatment and was main-
tained throughout the duration of the 8-week study. In a recent 
study in patients with severe incontinence awaiting surgery, 86% 
of women that responded to duloxetine responded within 1 week 
and 100% of women that responded, responded within 2 
weeks.23
  Urinary incontinence is a psychologically distressing, socially 
secluding, and potentially disabling condition. In Western coun-
tries the impact of urinary incontinence on quality of life has 
been compared to the impact of diabetes on quality of life.24,25 
Baseline measurements of total I-QoL scores in the Korean 
women in this study demonstrated that these women viewed 
their quality of life as more impaired even though they reported 
fewer IEF/week (approximately 12 vs 17 IEF/week, respec-
tively) than 1,913 women in an integrated analysis of 4 other 
studies (duloxetine=63.81; placebo=64.06).12-15 However, during 
the study the improvement of quality of life was substantial even 
in subjects treated with placebo. This phenomenon is often seen 
in treatment naive women and it is related to the active 
participation in the trial and exposure to the research setting: 
the Hawthorne effect. We did not monitor the experience with 
PFMT, but only 5 of the 121 women had had previous con-
tinence surgery.
  Duloxetine-associated improvements were numerically pre-
sent but not statistically significant for quality of life as measured 
by total I-QoL score, 2 of the I-QoL subscale scores, and PGI-I. 
However, this study was not powered to detect changes in I-QoL. 
In 3 of 4 core registration trials powered to detect changes in 
I-QoL, duloxetine treatment resulted in significant improvements 
in I-QoL total and subscale scores.12,15
  As in the other studies, incontinence improved despite signi-
ficant increases in voiding intervals with duloxetine, indicating 
the improvement did not result from more frequent emptying 
of the bladder.
  Overall, fewer Korean women reported at least 1 TEAE than 
in previous studies; however, Korean women reporting a TEAE 
were more likely to discontinue,12-15 suggesting that the Korean 
women perceived the adverse events as more severe. Unlike 
previous studies, this study did not have a 2-week placebo 
lead-in phase. Lack of the placebo lead-in phase may increase 
the number of TEAEs reported. Mean body mass index (BMI) 
of the Korean women was lower than the mean BMI of women 
in other studies which could suggest that the increased number 
of TEAEs and discontinuations may also be related to the lower 
BMI.
  Nausea was the most frequent adverse event associated with 
duloxetine treatment. Nausea tended to have a fast onset after 
initiation of duloxetine treatment. It was mild to moderate in 
most cases, did not worsen after its onset, and resolved within 
1 week to 1 month of therapy in most cases. A recent clinical 
trial demonstrated duloxetine dose escalation from 20mg twice 
daily to 40mg twice daily over 2 weeks may be an effective 
tactic to diminish but not eliminate the risk of nausea.26 
Consequently, combining proactive counselling about the natural 
history of nausea when taking duloxetine (mild to moderate, 
non-progressive, and transient) with dose escalation may de-
crease incidents of nausea and discontinuation prior to achieving 
duloxetine-associated benefits.
  Other common TEAEs included dizziness, anorexia, fatigue, 
lethargy, abdominal discomfort, somnolence, constipation, 
headache, and dry mouth. These data are largely consistent with 
published data from Africa, Australia, Europe, and North and 
South America.12-15 TEAEs including anorexia and abdominal 
discomfort are observed at much lower percentage rates in other 
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studies. It is possible that the increased rate is reflective of the 
small number of women in the study. The improvement asso-
ciated with duloxetine treatment must be weighed against a 
considerable discontinuation rate due to early adverse events. 
  This study was conducted in response to a request from the 
local Korean regulatory authorities. It is the first comprehensive 
study of the safety and efficacy of duloxetine in Korean women. 
The safety measures and the primary efficacy variable 
demonstrated that duloxetine was safe and efficacious for the 
treatment of SUI in Korean women; however, lack of statistical 
significance but numerical improvements in the secondary 
efficacy variables may have been a result of small sample sizes 
and a notable placebo effect27 in these women.
CONCLUSIONS
  These data support the conclusion that duloxetine has demon-
strated similar statistically significant and clinically relevant 
efficacy in Korean women with SUI as has been demonstrated 
in women in Africa, Australia, Europe, and North and South 
America. Adverse events were common but not serious. Duloxe-
tine administered at 40mg twice daily up to 8 weeks for the 
treatment of Korean women with SUI is safe and efficacious. 
Finally, the data also support the conclusion that the findings 
from studies in other populations can be reasonably extrapolated 
to the Korean population.
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